License agreement for COVID-19 drug 2-DG

License agreement for COVID-19 drug 2-DG

Question : Which pharma company has recently(July 2021) inked license agreement with DRDE & INMAS to produce,distribute & market COVID-19 drug 2-DG ?
a. Glenmark Pharma
b. Sun Pharma
c. BDR Pharma
d. Cadila
Ans. c.
Related facts —

  • BDR Pharma has recently(July 2021) inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
  • It is notable that last month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild to severe COVID-19 patients.
  • BDR Pharma has already applied to the Drug Controller General of India (DCGI) for restricted emergency use authorisation to manufacture Drug 2-DG to treat COVID-19 patients in India.
  • COVID-19 drug 2-Deoxy-D-Glucose (2-DG) would be priced competitively and will be available in powder form in a sachet that can be consumed orally after being dissolved in water.

DRDE —

  • Defence Research & Development Establishment is an Indian defence laboratory of the Defence Research and Development Organisation.
  • Located in Gwalior, it is primarily involved in the research and development of detection and protection against toxic chemical and biological agents.

INMAS —

  • Institute of Nuclear Medicine & Allied Sciences is a laboratory of the Defence Research and Development Organisation.
  • Located in Timarpur, Delhi, it is involved in Nuclear medicine research and responding to nuclear accidents and explosions.

By — Pankaj Pandey.

Link:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharma-inks-license-agreement-with-drdo-to-produce-covid-19-drug-2-dg/articleshow/84753067.cms